EUCTR2015-001530-25-Outside-EU/EEA进行中（未招募）不适用
A Phase IIIb, open, randomized, controlled, multicenter study of the immunogenicity and safety of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine (Havrix) [720 El.U/ 0.5 mL dose] administered on a 0, 6-month schedule concomitantly with GlaxoSmithKline Biologicals' DTaP vaccine (Infanrix) and Aventis Pasteur's Haemophilus b conjugate (Tetanus Toxoid Conjugate) vaccine (ActHIB) in healthy children 15 months of age. - HAV-232
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 468
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Only subjects whose parents/guardians are believed by the investigator to be willing to comply with the requirements of the protocol should be enrolled in the study,
- •A male or female child 12 or 13 months of age [i.e., subjects who have achieved their 12-month birthday but not yet achieved their 14-month birthday] at the time of entry into the Enrollment Phase,
- •Subjects must have previously received three doses each of DTaP and Hib vaccines during the first year of life. The three doses of DTaP vaccine must have been administered as either Infanrix or Pediarix® and the three doses of Hib vaccine must have been administered as ActHIB, HibTITER®, OmniHIB®
- •Subjects who, at 15 months of age, will have had at least six months elapse since their third dose of Infanrix or Pediarix,
- •Written informed consent obtained from the parents or guardian of the subject,
- •Free of obvious health problems as established by medical history and history-directed physical examination before entering into the study, and
- •Parents/guardian of the subject must have a telephone or be able to be contacted by telephone.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 468
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Use of any investigational or non-registered drug or vaccine other than the study vaccin(s within 31 days preceding the first dose of study vaccine, or planned use during the study period,
- •Chronic administration of immuno-suppressant or other immune-modifying drugs within six months prior to vaccination or planned administration at any time during the study period.
- •Planned administration or administration of any vaccine not foreseen by the study protocol during the period 42 days before and 31 days after each dose of study vaccines should be administered before or during the Enrollment Phase of the study but >= 42 days prior to administration of study vaccines at Day 0.
- •In order to comply with the ACIP-recommended admini-stration of Hib vaccine during the age range of 12-15 months, subjects in the HAV Group ONLY should receive their fourth dose of the Hib vaccine as commercially-available ActHIB during the interval between Visit 3 of the Active Phase and the subject's 19-month birthday.
- •Previous vaccination against DTaP using a commercially-available brand other than Infanrix or Pediarix or against Hib using a commercially-available brand other than ActHIB, HibTITER or OmniHIB.
- •Previous vaccination with more than three doses of DTaP-containing vaccines or more than three doses of Hib-containing vaccines.
- •Previous vaccination against hepatitis A,
- •History of hepatitis A,
- •Known exposure to hepatitis A,
- •History of diphtheria, tetanus, pertussis and/or Haemo-philus influenza type b,
- •Known exposure to diphtheria, tetanus, pertussis and/or Haemophilus influenza
- •type b within 31 days prior to the start of the study,
- •History of non-response to any vaccine in the current routine immunization schedule,
- •Any confirmed or suspected immunosuppressive or im-munodeficient condition, including human immunodefi-ciency virus infection,
- •A family history of congenital, hereditary or infectious immunodeficiency or parental risk factors for HIV infection,
- •History of allergic disease/reactions or hypersensitivity likely to be exacerbated by any component of Havrix, Infanrix or ActHIB including 2-phenoxyethanol, neomycin and gelatin,
- •History of hypersensitivity/allergic reaction to latex. Note: The tip cap and the rubber plunger of the Havrix and Infanrix needleless pre-filled syringes and the stopper of the ActHIB diluent vial contain dry natural latex rubber.
- •Major congenital defects or serious chronic illness,
- •History of any neurologic disorder.,
- •Acute disease at the time of vaccination.
- •Administration of immunoglobulins and/or any blood products within three months prior to the first dose of study vaccine or planned administration at any time during the entire study period, i.e., the Enrollment Phase, the Active Phase and the Extended Safety Follow-up Phase.
研究者
相似试验
进行中（未招募）
不适用
Immunogenicity and safety of GlaxoSmithKline Biologicals' Havrix administered on a 0, 6-month schedule concomitantly with Merck and Company, Inc. M-M-R II and Merck and Company, Inc. VARIVAX to healthy children 15 months of ageActive immunization against hepatitis A of healthy children 15 months of age at the time of the first study vaccination.EUCTR2015-001509-15-Outside-EU/EEAGlaxoSmithKline Biologicals1,474
进行中（未招募）
不适用
Immunogenicity, safety and reactogenicity of GSK Biologicals’ Hib-MenCY-TT vaccine 792014 compared to Merck & Co, Inc. Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) vaccine in healthy infants and toddlers.invasive diseases caused by Haemophilus influenzae type b (Hib) and Neisseria meningitidis serogroups C (MenC) and Y (MenY)EUCTR2013-003459-39-Outside-EU/EEAGlaxoSmithKline Biologicals600
进行中（未招募）
不适用
Immunogenicity & safety study of a booster dose of GSK Biologicals’ meningococcal vaccine 134612 given at 12-15 months of age or at 15-18 months of age (co-administered with Infanrix®) in primed healthy toddlersHealthy volunteers (for active immunization against N. meningitidis serogroups A, C, W-135 and Y when given as a booster dose for the MenC and MenY antigens and as a priming dose for the MenA and MenW-135 antigens in toddlers 12 to 18 months of age who were primed in infancy with Hib-MenCY-TT and Pediarix® at 2, 4, and 6 months of age)MedDRA version: 18.0Level: LLTClassification code 10028911Term: Neisseria meningitidis infection NOSSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10070124Term: Neisseria meningitidis test positiveSystem Organ Class: 100000004848EUCTR2012-002401-22-Outside-EU/EEAGlaxoSmithKline Biologicals1,558
进行中（未招募）
不适用
Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ meningococcal vaccine with or without co-administration of a licensed viral vaccine and Boostrix in female adolescents and young adults.Meningococcal diseaseMedDRA version: 16.1Level: LLTClassification code 10028911Term: Neisseria meningitidis infection NOSSystem Organ Class: 100000004862MedDRA version: 16.1Level: LLTClassification code 10032810Term: Other specified meningococcal infectionsSystem Organ Class: 100000004862MedDRA version: 16.1Level: LLTClassification code 10070124Term: Neisseria meningitidis test positiveSystem Organ Class: 100000004848EUCTR2012-001876-13-EEGlaxoSmithKline Biologicals1,300
进行中（未招募）
1 期
A phase III, open, randomized, controlled, multicentre, primary & booster study to demonstrate the non-inferiority of the MenC & Hib immune responses of GSK Biologicals’ Hib-MenC vaccine co-administered with Infanrix™ penta versus NeisVac-C™ co-administered with Infanrix™ hexa when given as 2 primary doses at 3, 5 m of age & prior to a booster dose at 11 m, as well as the immunogenicity of the Hib-MenC vaccine given as a booster at 11 m & the persistence of antibodies prior to the booster dose. - Hib-MenC-TT-014; Hib-MenC-TT-015 BST: 014EUCTR2005-005421-59-FIGlaxoSmithKline Biologicals709